The deal will enhance Kiromic's efforts to develop AI technology for selecting the optimal biomarkers needed for immunotherapeutics such as CAR T-cell therapy, according to the company.

Image courtesy of Kiromic.

InSilico's analytical tools enable the extraction of biological information from various genomic data sources. Kiromic said it is focusing now on developing models using whole-genome sequencing, RNA sequencing, single-cell RNA sequencing, cytometry, and cytokine panels to assist in selecting donor T cells with the strongest therapeutic potential.

Data from clinical trials will be utilized to improve treatment protocols and patient selection, according to InSilico. The goal is to accelerate therapeutic development, manufacturing, and clinical testing of Kiromic's off-the-shelf allogeneic CAR T for solid tumors, the firm said.

AI drug development startups raised $2.1B in 1st half of 2021
The market for artificial intelligence (AI) in drug development and discovery has been red-hot in recent years. The potential impact that AI can offer...

Kiromic BioPharma begins clinical manufacturing of gamma-delta T cells
Immuno-oncology firm Kiromic BioPharma has completed and certified its good manufacturing practice facility in Houston, TX. The facility will be used...

Kiromic submits 2 IND applications to FDA
Kiromic BioPharma has submitted two investigational new drug (IND) applications to the U.S. Food and Drug Administration (FDA) for its programmed cell...